Zobrazeno 21 - 30
of 666
pro vyhledávání: ''
Integrating data from multidisciplinary Management of Malignant Pleural Mesothelioma: a cohort study
Autor:
Patrizia Comoli, Pietro Rinaldi, Giulia Maria Stella, Francesco Agustoni, Patrizia Morbini, Chandra Bortolotto, Cristiano Primiceri, Elia Fraolini, David Michael Abbott, Dimitrios Eleftheriou, Laura Saracino, Andrea Riccardo Filippi, Giulia Accordino, Stefano Tomaselli, Matteo Bosio, Andrea Lancia, Emma Pozzi
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Background Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy that most commonly affects the pleural layers. MPM has a strong association with asbestos, mainly caused by exposure to its biopersistent fibers in at least 80% of ca
Autor:
Dejun Zhang, Lei Zhao, Qingling Hua, Zhenyu Lin, Tao Zhang, Guoliang Pi, Jiayuan Chen, Haihong Wang, Dandan Yu
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Background Modified FOLFIRINOX and gemcitabine plus nab-paclitaxel (GEM-NAB) have been recommended as first-line therapies for advanced pancreatic cancer (PC). Due to the lack of evidence to directly compare them, we conducted this network meta-analy
Autor:
Jing-Qiang Huang, Jun-Wei Song, Qiu-Yu Liu, Liang Wang, Peng Gong, Chun-Hui Zhou, He-Feng Li, Jing Zhu, Li-Yun Gong, Xian-Bin Zhang
Publikováno v:
Journal of Translational Medicine
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-14 (2021)
Journal of Translational Medicine, Vol 19, Iss 1, Pp 1-14 (2021)
Background Colorectal cancer is the third most common diagnosis. Oxaliplatin is used as first-line treatment of colon cancer. However, oxaliplatin resistance greatly reduces its therapeutic effect. SRPK1 involves in pre-mRNA splicing and tumorigenesi
Autor:
Mechthild Hatzfeld, Monika Haemmerle, Markus Glaß, Tony Gutschner, Matthias Kappler, W.G. Ballhausen, Alexander W. Eckert, Lisa Müller, Jonas Weiße, Julia Rosemann, Danny Misiak, Stefan Hüttelmaier
Publikováno v:
Molecular Cancer
Molecular Cancer, Vol 20, Iss 1, Pp 1-23 (2021)
Molecular Cancer, Vol 20, Iss 1, Pp 1-23 (2021)
Background Cancer metastases are the main cause of lethality. The five-year survival rate for patients diagnosed with advanced stage oral cancer is 30%. Hence, the identification of novel therapeutic targets is an urgent need. However, tumors are com
Autor:
Dongli Sun, Fengmei Wang, Caihong Zheng, Xiaodong Wu, Yunchun Zhao, Yao Yao, Chaoqun Li, Meng Zhang, Jiale Qin, Weidong Fei
Publikováno v:
Journal of Nanobiotechnology
Journal of Nanobiotechnology, Vol 19, Iss 1, Pp 1-21 (2021)
Journal of Nanobiotechnology, Vol 19, Iss 1, Pp 1-21 (2021)
Gestational trophoblastic tumors seriously endanger child productive needs and the health of women in childbearing age. Nanodrug-based therapy mediated by transporters provides a novel strategy for the treatment of trophoblastic tumors. Focusing on t
Autor:
Yu Hu, Liang V. Tang
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Cases of thrombotic thrombocytopenia induced by coronavirus disease 2019 (COVID-19) vaccines have been reported recently. Herein, we describe the first case of another critical disorder, hemophagocytic lymphohistiocytosis (HLH), in a healthy individu
Autor:
Olga Gielen, Inge Govaerts, Jan Cools, Kris Jacobs, Nancy Boeckx, Sarah Provost, David Nittner, Kim De Keersmaecker, Cristina Prieto, Johan Maertens, Heidi Segers, Charlien Vandersmissen
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-14 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-14 (2021)
Background T cell acute lymphoblastic leukemia (T-ALL) is a high-risk subtype that comprises 10–15% of childhood and 20–25% of adult ALL cases. Over 70% of T-ALL patients harbor activating mutations in the NOTCH1 signaling pathway and are predict
Autor:
Wenjin Yin, Jinsong Lu, Yueyao Du, Rui Sha, Jing Peng, Liheng Zhou, Fan Yang, Shuguang Xu, Yifan Wu, Huijuan Dai, Xiaonan Sheng, Yanping Lin
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-17 (2021)
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-17 (2021)
Background Triple negative breast cancer (TNBC) is a subtype of breast cancer with poor prognosis and lack of effective treatment target. Here we screened differentially expressed lncRNAs through bioinformatics analysis and identified CARMN as a down
Autor:
Linbo Wang, Shuduo Xie, Xun Zhang, Ji Wang, Zhaoqing Li, Misha Mao, Aihua Huang, Jichun Zhou, Lini Chen, Noor Ul Hassan Khan, Cong Chen, Jingjing Yang, Yulu Zhou, Yongxia Chen
Publikováno v:
Journal of Experimental & Clinical Cancer Research : CR
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-19 (2021)
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-19 (2021)
Background Ferroptosis is a newly defined form of regulated cell death characterized by the iron-dependent accumulation of lipid peroxidation and is involved in various pathophysiological conditions, including cancer. Targeting ferroptosis is conside
Autor:
Anna Mondino, Giulia Anderluzzi, Barbara Colombo, Alessandro Gori, Anna Gasparri, Angelo Corti, Flavio Curnis, Angelina Sacchi, Matteo Monieri
Publikováno v:
Journal of Nanobiotechnology, Vol 19, Iss 1, Pp 1-13 (2021)
Journal of nanobiotechnology 19 (2021). doi:10.1186/s12951-021-00871-y
info:cnr-pdr/source/autori:Corti A.; Sacchi A.; Gasparri A.M.; Monieri M.; Anderluzzi G.; Colombo B.; Gori A.; Mondino A.; Curnis F./titolo:Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR%2Fcytokine-coated nanogold/doi:10.1186%2Fs12951-021-00871-y/rivista:Journal of nanobiotechnology/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:19
Journal of Nanobiotechnology
Journal of nanobiotechnology 19 (2021). doi:10.1186/s12951-021-00871-y
info:cnr-pdr/source/autori:Corti A.; Sacchi A.; Gasparri A.M.; Monieri M.; Anderluzzi G.; Colombo B.; Gori A.; Mondino A.; Curnis F./titolo:Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR%2Fcytokine-coated nanogold/doi:10.1186%2Fs12951-021-00871-y/rivista:Journal of nanobiotechnology/anno:2021/pagina_da:/pagina_a:/intervallo_pagine:/volume:19
Journal of Nanobiotechnology
Background Gold nanospheres tagged with peptides containing isoDGR (isoAsp-Gly-Arg), an αvβ3 integrin binding motif, represent efficient carriers for delivering pro-inflammatory cytokines to the tumor vasculature. We prepared bi- or trifunctional n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ae24de8cb0ce71c4df99583b3de06fe
https://hdl.handle.net/2434/960038
https://hdl.handle.net/2434/960038